BridgeBio Pharma, Inc. Amortization of Debt Issuance Costs and Discounts
BridgeBio Pharma, Inc. (BBIO) reported Amortization of Debt Issuance Costs and Discounts of $3.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-10
- BridgeBio Pharma, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $1.93M, a 34.12% increase year-over-year.
- BridgeBio Pharma, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $1.82M, a 12.21% increase year-over-year.
- BridgeBio Pharma, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $1.45M, a 29.69% decline year-over-year.
- BridgeBio Pharma, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $1.46M, a 54.72% increase year-over-year.
- BridgeBio Pharma, Inc. amortization of debt issuance costs and discounts for fiscal 2025 was $5.97M, a 20.06% decline from fiscal 2024.
- BridgeBio Pharma, Inc. amortization of debt issuance costs and discounts for fiscal 2024 was $7.46M, a 16.20% decline from fiscal 2023.
- BridgeBio Pharma, Inc. amortization of debt issuance costs and discounts for fiscal 2023 was $8.91M, a 149.64% increase from fiscal 2022.
- BridgeBio Pharma, Inc. amortization of debt issuance costs and discounts for fiscal 2022 was $3.57M, a 6.95% increase from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 3 month as first filed | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 6 month as first filed | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 9 month as first filed | Amortization of Debt Issuance Costs and Discounts 12 month | Amortization of Debt Issuance Costs and Discounts 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $3.75M 10-Q · filed 2026-08-10 | $5.20M derived: sum of 3 quarters · filed 2026-08-10 | $6.66M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $1.82M 10-Q · filed 2026-05-07 | $3.27M derived: sum of 2 quarters · filed 2026-05-07 | $4.73M derived: sum of 3 quarters · filed 2026-05-07 | $6.17M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2025-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.91M derived: sum of 2 quarters · filed 2026-02-24 | $4.35M derived: sum of 3 quarters · filed 2026-02-24 | $5.97M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $2.90M derived: sum of 2 quarters · filed 2025-10-29 | $4.51M 10-Q · filed 2025-10-29 | $6.58M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2025-06-30 | $1.44M 10-Q · filed 2025-08-05 | $3.06M 10-Q · filed 2026-08-10 | $2.55M 10-Q · filed 2025-08-05 | $5.12M derived: sum of 3 quarters · filed 2026-05-07 | $6.07M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2025-03-31 | $1.62M 10-Q · filed 2026-05-07 | $1.11M 10-Q · filed 2025-04-29 | $3.69M derived: sum of 2 quarters · filed 2026-05-07 | $4.63M derived: sum of 3 quarters · filed 2026-05-07 | $5.57M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.01M derived: sum of 2 quarters · filed 2026-02-24 | $3.94M derived: sum of 3 quarters · filed 2026-02-24 | $7.46M 10-K · filed 2026-02-24 | $3.76M 10-K · filed 2025-02-20 | |||
| 2024-09-30 | $943.00K 10-Q · filed 2024-11-12 | $1.88M derived: sum of 2 quarters · filed 2025-08-05 | $5.40M 10-Q · filed 2025-10-29 | $2.81M 10-Q · filed 2024-11-12 | $8.98M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-06-30 | $937.00K 10-Q · filed 2025-08-05 | $1.87M 10-Q · filed 2025-08-05 | $8.04M derived: sum of 3 quarters · filed 2026-02-24 | $8.96M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $931.00K 10-Q · filed 2025-04-29 | $7.10M derived: sum of 2 quarters · filed 2026-02-24 | $8.02M derived: sum of 3 quarters · filed 2026-02-24 | $8.93M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.09M derived: sum of 2 quarters · filed 2026-02-24 | $8.00M derived: sum of 3 quarters · filed 2026-02-24 | $8.91M 10-K · filed 2026-02-24 | $3.66M 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $920.00K 10-Q · filed 2024-11-12 | $1.83M derived: sum of 2 quarters · filed 2024-11-12 | $2.74M 10-Q · filed 2024-11-12 | $3.64M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2023-06-30 | $913.00K 10-Q · filed 2024-08-01 | $1.82M 10-Q · filed 2024-08-01 | $2.72M derived: sum of 3 quarters · filed 2025-02-20 | $3.61M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2023-03-31 | $906.00K 10-Q · filed 2024-05-02 | $1.81M derived: sum of 2 quarters · filed 2025-02-20 | $2.70M derived: sum of 3 quarters · filed 2025-02-20 | $3.59M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2022-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $1.79M derived: sum of 2 quarters · filed 2025-02-20 | $2.69M derived: sum of 3 quarters · filed 2025-02-20 | $3.57M 10-K · filed 2025-02-20 | ||||
| 2022-09-30 | $895.00K 10-Q · filed 2023-11-02 | $1.78M derived: sum of 2 quarters · filed 2023-11-02 | $2.67M 10-Q · filed 2023-11-02 | $3.55M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-06-30 | $890.00K 10-Q · filed 2023-08-03 | $1.77M 10-Q · filed 2023-08-03 | $2.65M derived: sum of 3 quarters · filed 2024-02-22 | $3.52M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-03-31 | $883.00K 10-Q · filed 2023-05-04 | $1.76M derived: sum of 2 quarters · filed 2024-02-22 | $2.63M derived: sum of 3 quarters · filed 2024-02-22 | $3.50M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2021-12-31 | $878.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.75M derived: sum of 2 quarters · filed 2024-02-22 | $2.62M derived: sum of 3 quarters · filed 2024-02-22 | $3.34M 10-K · filed 2024-02-22 | ||||
| 2021-09-30 | $871.00K 10-Q · filed 2022-11-03 | $1.74M derived: sum of 2 quarters · filed 2022-11-03 | $2.46M 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | $867.00K 10-Q · filed 2022-08-04 | $1.59M 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | $720.00K 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |